Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients

Seizure

Volumn 16, Issue 5, 2007, Pages 402-409

  Heo, Kyoung ^a   Lee, Byung In ^a   Yi, Sang Do ^b   Huh, Kyoon ^c   Kim, Jae Moon ^d   Lee, Sang Ahm ^e   Shin, Dong Jin ^f   Song, Hong Ki ^g   Lee, Sang Kun ^h   Kim, Jeong Yeon ⁱ   Lu, Sarah ^j   Dubois, Cécilia ^j   Tonner, Françoise ^j  

^a Yonsei University College of Medicine   (South Korea)

^b Dongsan Medical Center   (South Korea)

^c Ajou University   (South Korea)

^d Chungnam National University College of Medicine   (South Korea)

^e Asan Medical Center   (South Korea)

^f Gachon University   (South Korea)

^g Kangdong Sacred Heart Hospital   (South Korea)

^h Seoul National University Hospital   (South Korea)

ⁱ Inje University College of Medicine   (South Korea)

^j UCB PHARMA   (Belgium)

more..

Author keywords

Add on therapy; Antiepileptic drugs; Epilepsy; Levetiracetam; Open label study; Partial seizures

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; BODY WEIGHT; BRAIN TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EOSINOPHIL COUNT; FATIGUE; FEMALE; FOCAL EPILEPSY; GLUCOSE BLOOD LEVEL; HEADACHE; HEMATOCRIT; HEMIPARESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INGUINAL HERNIA; INSOMNIA; KOREA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MENTAL DISEASE; MULTICENTER STUDY; NERVOUSNESS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VITAL SIGN;

ADULT; ANTICONVULSANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34249798721     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.02.011     Document Type: Article

References (22)

1. Patsalos P.N. Levetiracetam: chemistry, biotransformation, pharmacokinetics, and drug interactions. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs (2002), Lippincott Williams & Wilkins, Philadelphia 428-432
2. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 (1998) 191-206
3. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101 (2004) 9861-9866
4. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
5. Shorvon S.D., Löwenthal A., Janz D., Bielen E., Loiseau P., and for the European Levetiracetam Study Group. Multicentre double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
6. Ben-Menachem E., Falter U., and for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicentre, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
7. Otoul C., Arrigo C., van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005) 72-78
8. Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., and Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54 (2003) 153-161
9. -1 in adult patients with refractory epilepsy. Seizure 12 (2003) 141-149
10. Beran R.G., Berkovic S.F., Black A.B., Danta G., Hiersemenzel R., Schapel G.J., et al. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicentre, open-label single-arm study. Epilepsy Res 63 (2005) 1-9
11. Depondt C., Yuen A.W., Bell G.S., Mitchell T., Koepp M.J., Duncan J.S., et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 77 (2006) 101-103
12. Krakow K., Walker M., Otoul C., and Sander J.W. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
13. Ben-Menachem E., and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12 (2003) 131-135
14. Betts T., Yarrow H., Greenhill L., and Barrett M. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure 12 (2003) 136-140
15. Nicolson A., Lewis S.A., and Smith D.F. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 63 (2004) 568-570
16. Mohanraj R., Parker P.G., Stephen L.J., and Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 14 (2005) 23-27
17. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizure. Epilepsia 22 (1981) 489-501
18. Yoo H.J., Lee S.A., Heo K., Kang J.K., Ko R.W., Yi S.D., et al. The reliability and validity of Korean QOLIE-31 in patients with epilepsy. J Korean Epilepsy Soc 6 (2002) 45-52 [in Korean]
19. Cramer J.A., Perrine K., Devinsky O., Bryant-Comstock L., Meador K., and Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 39 (1998) 81-88
20. Genton P., Sadzot B., Fejerman N., Peltola J., Despland P.A., Steinhoff B., et al. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand 113 (2006) 387-394
21. Biton V. Levetiracetam: adverse experiences. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic drugs (2002), Lippincott Williams & Wilkins, Philadelphia 442-447
22. Tsai J.J., Yen D.J., Hsih M.S., Chen S.S., Hiersemenzel R., Edrich P., et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicentre, randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 72-81